equipment, and supplies company with annual revenue of $60 million, has entered into an amendment with Gemini Finance Corp. regarding its existing loan agreement and promissory note. According to ...

The financing duration has been extended until the end of the year, with the promissory note used as collateral now valued at SAR 935 million.

The obligation will be structured as a promissory note for a fixed amount with a six-year term. The annual payments under the note “shall be an amount equal to the difference between [the ...

Revenues Increased 21% and Gross Profit Increased 56% Generated Fourth Quarter Adjusted EBITDA of $1.1 Million ADT Acquisition ...

Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration ...

Fortified Balance Sheet of $113.0 Million Enables Company to continue R&D activities in AI-Driven Customer Platform in other ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference ...

Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple Categories Announces First VLN® Partner Brands ...

Convertible Series A Preferred Shares (NIS 0.09 par value, 0 and 56,667 shares authorized as of December 31, 2024 and 2023, 0 and 43,121 shares issued and outstanding as of December 31, 2024 and ...

Fortified Balance Sheet of $113.0 Million Enables Company to continue R&D activities in AI-Driven Customer Platform in other Corporate Initiatives 2024 Annual Meeting of Stockholders Scheduled for ...

Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse ...

HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential ...